Ключевые слова
психиатрия
шизофрения
комплаенс
психические расстройства
психофармакотерапия
шизофрения
комплаенс
психические расстройства
психофармакотерапия
Как цитировать
Белокрылов И. В., Соколов В. П. Проблема комплаенса в психиатрии // Кремлевская медицина. Клинический вестник. 2019. Т. № 1. С. 92-98.
Аннотация
В данной статье представлен обзор основных российских и зарубежных литературных источников, посвященных проблемам проверженности лечению (комплаенса) у пациентов, страдающих психическими расстройствами, в частности шизофренией. В статье описаны основные факторы, ассоциированные с отказом больного от назначенного лечения, описан вклад низкой комплаентности не только в качество жизни пациента, но и в расходы системы здравоохранения, связанные с повторными госпитализациями некомплаентных пациентов. В статье также рассматриваются методы оценки комплаенса: как экспериментальные, так и клинико-психологические, имеющие прикладное клиническое значение. Кроме того, в статье изучаются ме-тоды преодоления нонкомплаентности у больных шизофренией, например, комплаенс-терапия – психотерапевтическая методика, отличавшаяся краткосрочностью, удобством и простотой для применения в клинической практике, и показавшая до-статочно высокую эффективность.Литература
1. Незнанов Н.Г., Вид В.Д. Проблема комплаенса в клинической психиатрии. Психиатрия и психофармакология. 2004; 6(11):159-162.
2. Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2013;39: 999–1007. doi: 10.1093/schbul/sbs116.
3. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry. 2004;161(4): 692–699 doi: 10.1176/appi.ajp.161.4.692.
4. Лутова Н.Б. Структура комплаенса у больных с эндогенными психическими расстройствами. Диссертация на соискание ученой степени доктора медицинских наук - Санкт-Петербург: НМИЦ ПН им. В.М. Бехтерева, 2013. 375 с.
5. San L, Bernardo M, Gómez A, Martinez P, González B, Peña M. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord. J. Psychiatry. 2013; 67(1):22–29 doi: 10.3109/08039488.2012.667150.
6. Becker MA, Young MS, Ochshorn E, Diamond RJ. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm. Policy Ment. Health. 2007; 34(3): 307–314.doi:10.1007/s10488-006-0108-5.
7. Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J. Clin. Psychiatry. 2008;69(1): 74–80. doi: 10.4088/jcp.v69n0110.
8. Бугрова Е.И. Несоблюдение режима внебольничной психофармакотерапии больными шизофренией: социальные и экономические аспекты. Диссертация на соискание ученой степени кандидата медицинских наук. М., 2007. Московский НИИ Психиатрии. 151 с.
9. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br. J.Psychiatry Suppl. 2009; 52: S43–S50. doi: 10.1192/bjp.195.52.s43.
10. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists’use, knowledge and attitudes to first- and second-generation antipsychoticlong-acting injections: comparisons over 5 years. J Psychopharmacol.2009; 24: 1473–1482. doi: 10.1177/0269881109104882.
11. Мосолов С.Н. Современный этап развития психофармакотерапии. Русский медицинский журнал. 2002;10(12/13): 45-49.
12. Karow A, Reimer J, König HH, Heider D, Bock T, Huber C et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012; 73(3): 402–408. doi: 10.4088/jcp.11m06875.
13. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013; 7: 247–254. doi: 10.1111/eip.12027.
14. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010; 175: 58–62 doi: 10.1016/j.psychres.2008.11.003.
15. Данилов Д.С. Терапия шизофрении. М: Миклош 2010. 276 с.
16. Kotzè AM, van Delft WF, Roos JL. Continuity of care of outpatients with schizophrenia in Pretoria. S. Afr. J. Psychiatr. 2010;16(3): 80–83 doi: 10.4102/sajpsychiatry.v16i3.272.
17. Иржевская В.П. Нарушения осознания психической болезни при шизофрении - диссертация на соискание ученой степени кандидата медицинских наук. МГУ им. М. В. Ломоносова;2009. 212 c.
18. Valenstein M, McCarthy JF, Ganoczy D, Bowersox NW, Dixon LB, Miller R et al. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv. 2013; 64(5): 445–451. doi: 10.1176/appi.ps.201100543.
19. Pinto E, Sahoo S, Deshmukh D, Vadlamani N, Dhingra I, Karia S et al. Treatment compliance and noncompliance in psychosis: Methodological issues. Indian J Psychiatry. 2017; 59(3): 401–402 doi: 10.4103/psychiatry.indianjpsychiatry_343_17.
20. Rodrigo C, Welgama S, Wijeratne T, Weligepola R, Rajapakse S, Jayananda G. A prospective cohort study on the role of nonspecialist staff in preventing relapses and improving clinic attendance of patients with schizophrenia. Indian J Psychiatry. 2013; 55(1): 74–76 doi: 10.4103/0019-5545.105518.
21. Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ et al. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Prefer Adherence. 2011; 5: 547–554 doi: 10.2147/ppa.s23255.
22. McHugo GJ, Bebout RR, Harris M, Cleghorn S, Herring G, Xie H et al. A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness. Schizophr Bull. 2004; 30(4):969–982 doi: 10.1093/oxfordjournals.schbul.a007146.
23. De Las Cuevas C, de Leon J, Peñate W, Betancort M Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017; 11: 681–690. doi: 10.2147/ppa.s133513.
24. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010; 26: 501–509. doi:10.1185/03007990903488670.
25. Vervloet M, Linn AJ, van Weert JC, de Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012; 19: 696–704 doi: 10.1136/amiajnl-2011-000748.
26. Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res. 2012; 200:89–95. doi: 10.1016/j.psychres.2012.07.034.
27. McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009; 65(3): 534–543. doi: 10.1111/j.1365-2648.2008.04906.x.
28. Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res. 2012; 200: 83–8. doi: 10.1016/j.psychres.2012.03.033.
29. Manuel JI, Covell NH, Jackson CT, Essock SM. Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? J Am Psychiatr. Nurses. Assoc. 2011; 17(1): 51–56. doi:10.1177/1078390310395586.
30. Aagaard J, Müller-Nielsen K. Clinical outcome of assertive community treatment (ACT) in a rural area in Denmark: a case-control study with a 2-year follow-up. Nord J Psychiatry. 2011; 65(5): 299–305. doi: 10.3109/08039488.2010.544405.
31. Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A.. The influence of perceived social support on medication adherence in first episode psychosis. Can J Psychiatry. 2013; 58(1): 59–65. doi:10.1177/070674371305800111.
32. Wilk JE, West JC, Marcus SC, Countis L, Regier DA, Olfson M. Family contact and the management of medication non-adherence in schizophrenia. Community Ment Health J. 2008; 44(5): 377–380. doi: 10.1007/s10597-008-9139-6.
33. Кемп Р., Девид А., Хейворд П. Комплайенс-терапия. Обзор современ. психиатрии. 2000; 5: 91-101.
34. Бабин С.М., Шлафер А.М., Сергеева Н.А., Комплаенс-терапия больных шизофренией [электронный ресурс]. Медицинская психология в России: электронный научный журнал 2011. 2. http:// medpsy.ru.
35. Krzystanek M, Krysta K, Skałacka K. Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study. J Technol Behav Sci. 2017; 2(2): 84–87. doi: 10.1007/s41347-017-0016-4.
2. Velligan D, Mintz J, Maples N, Xueying L, Gajewski S, Carr H et al. A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia. Schizophr Bull. 2013;39: 999–1007. doi: 10.1093/schbul/sbs116.
3. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am. J. Psychiatry. 2004;161(4): 692–699 doi: 10.1176/appi.ajp.161.4.692.
4. Лутова Н.Б. Структура комплаенса у больных с эндогенными психическими расстройствами. Диссертация на соискание ученой степени доктора медицинских наук - Санкт-Петербург: НМИЦ ПН им. В.М. Бехтерева, 2013. 375 с.
5. San L, Bernardo M, Gómez A, Martinez P, González B, Peña M. Socio-demographic, clinical and treatment characteristics of relapsing schizophrenic patients. Nord. J. Psychiatry. 2013; 67(1):22–29 doi: 10.3109/08039488.2012.667150.
6. Becker MA, Young MS, Ochshorn E, Diamond RJ. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm. Policy Ment. Health. 2007; 34(3): 307–314.doi:10.1007/s10488-006-0108-5.
7. Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. J. Clin. Psychiatry. 2008;69(1): 74–80. doi: 10.4088/jcp.v69n0110.
8. Бугрова Е.И. Несоблюдение режима внебольничной психофармакотерапии больными шизофренией: социальные и экономические аспекты. Диссертация на соискание ученой степени кандидата медицинских наук. М., 2007. Московский НИИ Психиатрии. 151 с.
9. Waddell L, Taylor M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br. J.Psychiatry Suppl. 2009; 52: S43–S50. doi: 10.1192/bjp.195.52.s43.
10. Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists’use, knowledge and attitudes to first- and second-generation antipsychoticlong-acting injections: comparisons over 5 years. J Psychopharmacol.2009; 24: 1473–1482. doi: 10.1177/0269881109104882.
11. Мосолов С.Н. Современный этап развития психофармакотерапии. Русский медицинский журнал. 2002;10(12/13): 45-49.
12. Karow A, Reimer J, König HH, Heider D, Bock T, Huber C et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012; 73(3): 402–408. doi: 10.4088/jcp.11m06875.
13. Emsley R, Chiliza B, Asmal L, Mashile M, Fusar-Poli P. Long-acting injectable antipsychotics in early psychosis: a literature review. Early Interv Psychiatry. 2013; 7: 247–254. doi: 10.1111/eip.12027.
14. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010; 175: 58–62 doi: 10.1016/j.psychres.2008.11.003.
15. Данилов Д.С. Терапия шизофрении. М: Миклош 2010. 276 с.
16. Kotzè AM, van Delft WF, Roos JL. Continuity of care of outpatients with schizophrenia in Pretoria. S. Afr. J. Psychiatr. 2010;16(3): 80–83 doi: 10.4102/sajpsychiatry.v16i3.272.
17. Иржевская В.П. Нарушения осознания психической болезни при шизофрении - диссертация на соискание ученой степени кандидата медицинских наук. МГУ им. М. В. Ломоносова;2009. 212 c.
18. Valenstein M, McCarthy JF, Ganoczy D, Bowersox NW, Dixon LB, Miller R et al. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication. Psychiatr Serv. 2013; 64(5): 445–451. doi: 10.1176/appi.ps.201100543.
19. Pinto E, Sahoo S, Deshmukh D, Vadlamani N, Dhingra I, Karia S et al. Treatment compliance and noncompliance in psychosis: Methodological issues. Indian J Psychiatry. 2017; 59(3): 401–402 doi: 10.4103/psychiatry.indianjpsychiatry_343_17.
20. Rodrigo C, Welgama S, Wijeratne T, Weligepola R, Rajapakse S, Jayananda G. A prospective cohort study on the role of nonspecialist staff in preventing relapses and improving clinic attendance of patients with schizophrenia. Indian J Psychiatry. 2013; 55(1): 74–76 doi: 10.4103/0019-5545.105518.
21. Chen J, Ascher-Svanum H, Nyhuis AW, Case MG, Phillips GA, Schuh KJ et al. Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians. Patient Prefer Adherence. 2011; 5: 547–554 doi: 10.2147/ppa.s23255.
22. McHugo GJ, Bebout RR, Harris M, Cleghorn S, Herring G, Xie H et al. A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness. Schizophr Bull. 2004; 30(4):969–982 doi: 10.1093/oxfordjournals.schbul.a007146.
23. De Las Cuevas C, de Leon J, Peñate W, Betancort M Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017; 11: 681–690. doi: 10.2147/ppa.s133513.
24. Peuskens J, Olivares JM, Pecenak J, Tuma I, Bij de Weg H, Eriksson L et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010; 26: 501–509. doi:10.1185/03007990903488670.
25. Vervloet M, Linn AJ, van Weert JC, de Bakker DH, Bouvy ML, van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012; 19: 696–704 doi: 10.1136/amiajnl-2011-000748.
26. Montes JM, Medina E, Gomez-Beneyto M, Maurino J. A short message service (SMS)-based strategy for enhancing adherence to antipsychotic medication in schizophrenia. Psychiatry Res. 2012; 200:89–95. doi: 10.1016/j.psychres.2012.07.034.
27. McCann TV, Clark E, Lu S. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia. J Adv Nurs. 2009; 65(3): 534–543. doi: 10.1111/j.1365-2648.2008.04906.x.
28. Jaeger S, Pfiffner C, Weiser P, Kilian R, Becker T, Längle G et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res. 2012; 200: 83–8. doi: 10.1016/j.psychres.2012.03.033.
29. Manuel JI, Covell NH, Jackson CT, Essock SM. Does assertive community treatment increase medication adherence for people with co-occurring psychotic and substance use disorders? J Am Psychiatr. Nurses. Assoc. 2011; 17(1): 51–56. doi:10.1177/1078390310395586.
30. Aagaard J, Müller-Nielsen K. Clinical outcome of assertive community treatment (ACT) in a rural area in Denmark: a case-control study with a 2-year follow-up. Nord J Psychiatry. 2011; 65(5): 299–305. doi: 10.3109/08039488.2010.544405.
31. Rabinovitch M, Cassidy C, Schmitz N, Joober R, Malla A.. The influence of perceived social support on medication adherence in first episode psychosis. Can J Psychiatry. 2013; 58(1): 59–65. doi:10.1177/070674371305800111.
32. Wilk JE, West JC, Marcus SC, Countis L, Regier DA, Olfson M. Family contact and the management of medication non-adherence in schizophrenia. Community Ment Health J. 2008; 44(5): 377–380. doi: 10.1007/s10597-008-9139-6.
33. Кемп Р., Девид А., Хейворд П. Комплайенс-терапия. Обзор современ. психиатрии. 2000; 5: 91-101.
34. Бабин С.М., Шлафер А.М., Сергеева Н.А., Комплаенс-терапия больных шизофренией [электронный ресурс]. Медицинская психология в России: электронный научный журнал 2011. 2. http:// medpsy.ru.
35. Krzystanek M, Krysta K, Skałacka K. Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study. J Technol Behav Sci. 2017; 2(2): 84–87. doi: 10.1007/s41347-017-0016-4.